What most patients pay

Guide costs for ChondroFiller in the UK are structured around a straightforward three-tier model based on how many boxes of the collagen scaffold the treated area requires — not an hourly rate, a per-session charge, or a sliding-scale estimate.

• One box: £3,000
• Two boxes: £5,500
• Three boxes: £8,000

For most patients presenting with a single focal cartilage defect, one box is sufficient, placing the majority at the £3,000 guide cost — the lowest tier in the published range.

The number of boxes required is not left to the day of the appointment. It is confirmed at a pre-procedure imaging review that takes place before any booking is made, so patients enter the process knowing the full expected cost rather than discovering it at the clinic.

It is worth noting that fixed published pricing currently comes from a single London-based specialist clinic; no equivalent publicly available tariff exists for other UK providers. Patients seeking treatment elsewhere should request a written cost confirmation before committing — and should ensure the quote covers the same scope of care (consultation, imaging review, the injection appointment itself, and follow-up) rather than the implant cost alone.

What the guide cost includes

Regardless of which tier applies, the guide cost is documented as a single all-in figure — not a starting point to which additional charges are added. Published clinic information consistently describes the following as bundled within the quoted price:

• Initial consultation
• Pre-procedure imaging review
• Real-time ultrasound guidance during the injection appointment
• The ChondroFiller collagen scaffold implant itself
• Intravenous antibiotic cover on the day
• A six-week follow-up appointment

No separately billed day-of fees are documented in published sources.

The implant is the dominant cost component in that bundle. ChondroFiller is a CE-marked Class III medical device — the highest-risk tier under UK and EU implant regulation — manufactured by Meidrix Biomedicals GmbH in Germany and imported under prescription. Class III classification reflects the scaffold's active biological role: it gels in situ and recruits the patient's own progenitor cells through acellular matrix-induced chondrogenesis. That regulatory complexity, rather than a simple product markup, accounts for the cost difference between ChondroFiller and a standard intra-articular injection.

For larger or multi-compartment joints such as the hip or shoulder, at least one clinic has cited a broader indicative range of approximately £6,500–£9,500. This figure is less consistently confirmed across published sources than the standard three-tier model; patients considering treatment in these joints should request written cost confirmation from the treating clinic before proceeding.

Why ChondroFiller is not available on the NHS

ChondroFiller sits entirely outside NHS commissioning and is available only through private self-pay or private health insurance. That status is structural rather than a judgement on clinical merit: the NHS has its own cartilage pathway — autologous chondrocyte implantation (ACI), funded for eligible patients with specific knee cartilage defects since 2017 — and ChondroFiller occupies a different position in the regulatory and commissioning landscape.

The two treatments are not interchangeable options at the same decision point. ACI is a staged surgical procedure carried out in theatre and assessed for NHS funding against defined eligibility criteria. ChondroFiller is an injectable scaffold placed under ultrasound guidance as an outpatient procedure; it has not been evaluated through an NHS commissioning review, and no NICE guidance currently covers it.

Patients who want to explore NHS-funded cartilage repair should discuss ACI eligibility with their GP or through an orthopaedic referral. Those who do not meet the criteria, or who prefer to avoid a surgical pathway and a potentially lengthy waiting period, may find ChondroFiller a relevant option to explore privately — but that choice belongs with a specialist assessment, not a cost article.

Using private health insurance to cover the cost

Private health insurance may cover some or all of the procedure cost, and for insured patients a short pre-booking process can make a significant financial difference. Checking coverage before the appointment — not after — is the practical starting point.

In documented cases as of October 2025, Bupa, Aviva, and WPA are the UK insurers most commonly reported to have approved cover for ChondroFiller procedures. These are examples drawn from clinical experience, not a guarantee: coverage depends entirely on the individual policy, and partial cover is possible even where a claim is approved.

The most useful step when approaching an insurer is to ask the treating clinic for the relevant billing codes before making the call. Quoting the correct procedure codes allows the insurer to locate the right benefit within the policy and assess whether the treatment falls within scope. The clinic can advise which codes apply to the specific planned procedure.

Written pre-authorisation — confirmed in writing before attending — is always required. Treatment that goes ahead without a documented approval risks the full cost reverting to self-pay, regardless of what a telephone enquiry may have suggested.

Some insurers also ask for evidence that conservative management has already been tried before approving a regenerative procedure. Gathering relevant physiotherapy or GP records in advance can help support the application and avoid unnecessary delays.

How ChondroFiller cost compares to surgical cartilage repair

Surgical cartilage repair in the UK private sector — procedures such as osteochondral autograft transfer (OATS), autologous chondrocyte implantation (ACI), and osteochondral grafting — typically costs between £7,000 and £14,000. Beyond the headline figure, those pathways involve theatre admission, general anaesthetic, and a rehabilitation period measured in months rather than days.

ChondroFiller and surgical repair address different clinical situations. Surgical options are generally considered for larger, deeper, or structurally more complex defects; ChondroFiller as an injectable scaffold is assessed for focal lesions suited to an outpatient appointment under ultrasound guidance. Imaging review determines which route is clinically appropriate, and for some patients neither is the right answer. Cost is a useful reference point, not a deciding factor.

Where the injectable scaffold pathway is indicated, published evidence suggests 70–85% of patients achieve meaningful symptom relief at three to five years. No direct head-to-head trial compares that figure against equivalent surgical outcome rates, so it provides context for cost-value discussion rather than a superiority benchmark — a distinction worth raising during any specialist assessment.

At the other end of the spectrum, standard intra-articular injections such as hyaluronic acid and corticosteroid typically cost considerably less — often in the low hundreds of pounds per session. They act on symptoms rather than cartilage structure, and the price gap versus ChondroFiller reflects its Class III medical device classification and the regulatory and prescription-import requirements that come with it, rather than a simple mark-up on a commodity injectable.

Finding a UK specialist who offers ChondroFiller

Taking the next practical step means identifying a specialist with relevant experience in image-guided cartilage procedures — ideally one who regularly carries out the pre-procedure defect assessment, has access to ChondroFiller as a licensed implant, and can support insurer pre-authorisation where needed. Not every MSK clinic offers the treatment, so confirming this before booking is worthwhile.

When approaching a clinic, a few questions help establish what you are committing to: how defect size and box count are assessed, exactly what the quoted figure covers, and whether the practice has experience navigating insurer approvals for scaffold procedures. A written quote makes meaningful comparison possible if you are speaking to more than one provider.

A specialist consultation is the appropriate next step to confirm clinical suitability, establish the likely box requirement for your specific joint and defect, and receive a cost estimate specific to your situation — the guide costs in this article provide a reference range, not a personalised figure.

The Search MSK directory — a specialist-finder covering clinicians across the UK — lists practitioners who offer ChondroFiller and related cartilage treatments, searchable by region and specialty, making it straightforward to identify suitably experienced clinicians regardless of where you are based.